All In Biotech

Drug Trial Radar · NCT05420220

Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer

An Open-Label, Multi-Center, Phase 2 Clinical Study to Evaluate Efficacy, Safety, and Tolerability of KN046 in Combination With Axitinib in Subjects With Advanced Non-Small Cell Lung Cancer

Last checked: Nov 19, 2026Latest source record: May 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

95

Actual

Start

Jul 26, 2022

Primary completion

Dec 31, 2024

Study completion Dec 31, 2025

Sponsor

Sponsor type
Industry
First posted
Jun 15, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open-label, multi-center, Phase 2 study in subjects with treatment-naïve locally advanced (unresectable and unable to receive radical chemoradiotherapy) or metastatic PD-L1-positive non-small cell lung cancer (NSCLC) who have received systemic therapy.

Conditions

  • Advanced Non-small Cell Lung Cancer

Interventions

  • KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)Biological

    5 mg/kg Q3W IV

  • AxitinibCombination product

    5mg bid po

  • AxitinibCombination product

    3mg bid po

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to 2 years

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Linyi Cancer Hospital

    Linyi, Shandong, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

  • Shanghai Chest Hospital

    Shanghai, Shanghai Municipality, China

  • The first affiliated hospital, Zhejiang university

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.